Filing Flows › Health Care › Sight Sciences (SGHT)

Sight Sciences (SGHT) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Sight Sciences (SGHT) Q3 2026 earnings results →

Q3 2026 Revenue up 25% year over year to $24.9M · 27¢ of every $1 of revenue lost · operating margin -24.6%

Sight Sciences made $24.9M in Q3 2026 (+25% Y/Y): Surgical Glaucoma $21.0M, Dry Eye $3.9M. Operating margin -24.6%, net loss $6.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.

Revenue$24.9M

Year over year+25%

Operating margin-24.6%

Net earnings−$6.8M

Operating cash flow−$2.4M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $24.9M in Q3 2026, up 25% year over year and up 7% from the previous quarter. Surgical Glaucoma was the largest line at 84% of revenue. Dry Eye added $3.7M year over year (up 1962%), 74% of the total change.

Gross margin was 85.9%, down 0.4 points from Q3 2025. Operating costs exceeded revenue by $6.1M, an operating margin of -24.6%. Operating expenses grew 10% against revenue growth of 25%. The fastest-growing cost line was SG&A (+14%). The quarter ended with a net loss of $6.8M, wider than the previous quarter's $4.4M loss.

Operating cash flow was −$2.4M. Non-cash charges added back $110K of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items added $1.4M. Capital expenditures of $68K exceeded it, leaving free cash flow of −$2.5M.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	10-Q	Nov 4, 2026	$24.9M	+25%	-24.6%	−$6.8M	−$2.4M
Q2 2026	10-Q	Aug 5, 2026	$23.4M	+20%	-16.6%	−$4.4M	−$5.7M
Q1 2026	10-Q	May 6, 2026	$19.7M	+12%	-63.0%	−$13.0M	−$7.0M
Q4 2025	10-K	Mar 4, 2026	$20.4M	+7%	-18.0%	−$4.2M	−$1.8M
Q3 2025	10-Q	Nov 6, 2025	$19.9M	-1%	-39.7%	−$8.2M	−$8.7M
Q2 2025	10-Q	Aug 7, 2025	$19.6M	-8%	-59.6%	−$11.9M	−$7.5M
Q1 2025	10-Q	May 8, 2025	$17.5M	-9%	-79.2%	−$14.2M	−$11.6M

Charts

Latest (Q3 2026): Y/Y +25%, Q/Q +7%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income −$6.8M, Operating cash flow −$2.4M.

-7.1% since FY2020: buybacks shrank the count; earlier years scaled for the 2-for-1 split before FY2022, 3-for-1 split before FY2021.

Cash $92.0M, short-term investments —, long-term debt $42.4M at 2025-12-31.

Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.